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Richard ChamplinAllogeneic stem cell transplantation is a potentially curative treatment for myelodysplastic syndromes. Trans-
plants are clearly indicated in patients with intermediate-2 and high risk disease; there is controversy regard-
ing when transplantation should be performed in patients with low and intermediate-1 risk disease. Most
patients with MDS are over age 65 and Medicare has recently provisionally approved transplants, but only
when performed as part of a comparative clinical trial which still must be finalized. Nonmyeloablative pre-
parative regimens allow treatment of older patients with MDS, and novel approaches are under evaluation
to reduce the risk of relapse and treatment related morbidity and mortality.
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ily of clonal hematopoietic diseases characterized by
bone marrow failure and a predisposition to evolve
into acutemyelogenous leukemia [1].Despite themajor
progress in theunderstandingof thepathophysiologyof
MDS and recent advances in treatment, MDS remains
an incurable disease with standard forms of treatment.
The prognosis is related to the severity of pancytopenia,
cytogenetic abnormalities, and percentage of bone
marrow blasts. Prognostic indices have been developed
based on these features [2-4]. The widely used
International Prognostic Scoring System (IPSS),
developed in 1997, considers clinical features present
only at diagnosis. Some are concerned that the IPSS
undervalues the impact of adverse cytogenetics. MDS
occurring after previous chemotherapy (treatment- or
therapy-related MDS) is not considered in the IPSS
system; this has a poor prognosis even when presenting
with low-risk clinical features [4].
Subsequent indiceshave tried to refineprognostic as-
sessment, and the recently published M.D. Anderson
scoring system can be applied anywhere during the treat-
ment of the disease [4]. Allogeneic hematopoietic stem
cell transplantation (HSCT) is a potentially curative
treatment for MDS. HSCT is a high-risk procedure
that carries substantial risksof treatment-relatedmorbid-University of Texas M.D. Anderson Cancer Center,
ton, Texas.
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6/j.bbmt.2010.10.014ity andmortality. MDS is largely a disease of the elderly,
who often have comorbidities, and transplantation strat-
egies must address the unique needs of this population.
RESULTS OF ALLOGENEIC HSCT
Allogeneic HSCT is a potentially curative treat-
ment for MDS. Results are related to the prognostic
factors of the disease present at the time of transplan-
tation. Patients with low-risk IPSS scores have the best
results. The risks of relapse and treatment-related
mortality are increased in patients with more advanced
disease [5-10]. Prognosis is related to age, disease stage
at transplantation, cytogenetics, and ferritin level [11].
Transplantation can be successfully performed in
older patients who are in good general medical condi-
tion [7,12]. HSCT has been most successful when the
graft source is an HLA-matched related or unrelated
donor [13,14]; the success rate of HSCT with
unrelated transplants now nearly approaches that of
HSCT with matched sibling transplants.
Allogeneic HSCT also is potentially curative for
treatment-related MDS [15], with poor outcomes re-
lated to advanced age, cytogenetic abnormalities, lack
of an HLA-identical donor, and transformation to
AML [16]. The 5-year disease-free survival ranges
from 50% in the presence of only 1 of these risk
factors to 4% in the presence of all risk factors.INDICATIONS FOR HSCT
The indications for allogeneic HSCT are a matter
of debate, given the risks of the procedure and the re-
cent development of alternative therapeutic options. In
2004, Cutler et al. [17] reported a decision analysis in
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reported to the Center for International Blood and
Marrow Transplantation Research with the outcomes
of nontransplantation therapies from the IPSS analy-
sis. They found that HSCT was associated with im-
proved survival in patients with intermediate-2 and
high-risk disease, whereas patients with low-risk and
intermediate-1 MDS fared better with conservative
care (ie, without allogeneic HSCT), given the rela-
tively long natural history in this population. Patients
with intermediate-2 and high-risk MDS, which is
normally rapidly fatal, had improved survival with allo-
geneic HSCT. The decision analysis of Cutler et al.
[17] warrants reassessment, given the development of
improved prognostic indices and advances in both
HSCT and nontransplantation therapies, including
hypomethylating agents and lenalidomide.NONMYELOABLATIVE AND REDUCED-
INTENSITY PREPARATIVE REGIMENS
The development of reduced-intensity preparative
regimens has reduced the risk of treatment-related
mortality in HSCT [18]. These regimens typically
involve combinations of busulfan or melphalan with
fludarabine [19,20], those agents plus alemtuzumab
[21,22], or low-dose total-body irradiation and fludar-
abine [23]. The intensity of the regimen affects the risk
of relapse ofMDS.Relapse rates are higherwith lower-
intensity regimens, particularly in patients with ad-
vanced disease, although this effect is partially offset
by a lower risk of treatment-related mortality [23-26].INTEGRATING HSCT INTOTHE OVERALL
MANAGEMENTOF MDS
A major question is when to perform allogeneic
HSCT in patients presenting with low-risk or
intermediate-1 risk MDS. Although the analysis of
Cutler et al. [17] indicated no advantage to early allo-
geneic HSCT, these patients ultimately have a fatal
disease and have a better prognosis after transplanta-
tion compared with patients with more advanced
MDS. The clinical and biological factors that indicate
the need to proceed to transplantation remain to be de-
fined. Patients with low-risk MDS have an indolent,
but ultimately fatal disease. They are best treated con-
servatively at the time of diagnosis. Better criteria need
to be defined for assessing prognosis [27] and deter-
mining the optimum timing of HSCT in the course
of the disease. Results are best when HSCT is
performed without the presence of excess blasts and
before the transformation to AML. Patients who fail
to respond to hypomethylating agents or who lose their
response have a relatively poor prognosis and might
represent a category of patients in whom HSCT isindicated. Improved management of patients with
advanced MDS is needed. Whether a trial of
hypomethylating agent therapy will improve the
outcome of subsequent allogeneic HSCT is unknown.
Previous treatment with decitabine or azacitidine does
not appear to increase the toxicity of the transplant [28].MEDICARE INSURANCE COVERAGE
FOR MDS
Medicare currently covers allogeneic HSCT for
AML, but not for MDS, posing a major problem for
these predominantly older patients with Medicare as
their primary insurance. The Centers for Medicare
and Medicaid Services recently recommended provi-
sional approval with transplantation only as part of
a national study comparing allogeneic HSCT and
nontransplantation treatments. This trial is currently
in the organizational stage; the design is challenging.
Transplantation outcomes are routinely collected by
the CIBMTR as part of the national Stem Cell Trans-
plant Database. However, nontransplantation out-
comes are not routinely reported to any single
organization, and the analysis must adjust for known
prognostic factors. There is likely a referral bias that
patients being treated with hypomethylating agents
are likely to continue that treatment when doing well
and to be referred for HSCT if doing poorly.APPROACHES TO REDUCE RELAPSE
New preparative regimens that improve the eradi-
cation of MDS without increasing toxicity are needed.
The use of novel agents, such as tresulfan, in prepara-
tive regimen, is currently being evaluated [29]. Radio-
immunotherapy, with the addition of a radiolabeled
monoclonal antibody to CD45 to nonmyeloablative
regimens, is a promising approach [30].
Another potential strategy is the use of posttrans-
plantation maintenance therapy to prevent disease
recrudescence. Hypomethylating agents have been
shown to improve hematopoiesis and delay transfor-
mation to AML in the nontransplantation setting. de
Lima et al. [31] have evaluated the potential use of
azacitidine after allogeneic HSCT. This promising
approach is currently under study. Another major
research direction is the modulation of graft-versus-
malignancy effects through various measures.CONCLUSION
Allogeneic HSCT is a potentially curative treat-
ment for MDS. HSCT remains a high-risk treatment,
however, and careful selection of patients is mandatory
to ensure that this treatment approach is justified.
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treatment strategies are needed to reduce the risk of re-
lapse. Continued improvements in supportive care are
needed to prevent treatment-related morbidity and
mortality in the generally older patients with MDS.ACKNOWLEDGMENTS
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